Note 17 - Shareholders' Equity

12 Months Ended

Dec. 31, 2022

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

17. Shareholders’ Equity

Stock-based Compensation: On June 2, 2021, the Company’s stockholders approved the 2021 Equity Incentive Plan (the “2021 Plan”), which replaced the Amended and Restated 2012 Equity Incentive Plan (the “2012 Plan”) and no further awards may be granted under the 2012 Plan. The 2021 Plan provides for the issuance of restricted stock, RSUs and stock options to eligible employees and to members of our Board of Directors. A total of 2,689,909 shares of our common stock were reserved for issuance under the 2021 Plan of which 2,121,419 remained available as of December 31, 2022. During the years ended December 31, 2022, 2021 and 2020, we did not grant any stock options or restricted stock awards and as of  December 31, 2022, there were no stock options or restricted stock awards outstanding.

Restricted Stock Units: RSUs are issued for compensatory purposes. RSU stock compensation cost is measured at our common stock’s fair value based on the market price at the date of grant. We recognize stock compensation cost only for RSUs that we estimate will ultimately vest. We estimate the number of shares that will ultimately vest at each grant date based on our historical experience and adjust stock compensation cost based on changes in those estimates over time.

RSU stock compensation cost is recognized ratably over the shorter of the vesting period (generally ranging from immediate vesting to three years) or the period from grant date to the first maturity date after the holder reaches age 62 and has completed certain specified years of service, when all RSUs become fully vested. Vesting of RSUs is not subject to any market or performance conditions and vesting provisions are at the discretion of the Compensation Committee. A recipient of RSUs  may not sell or otherwise transfer unvested RSUs and, in the event a recipient’s employment or board service is terminated prior to the end of the vesting period, any unvested RSUs are surrendered to us, subject to limited exceptions.

A summary of the changes in our RSUs during the years ended  December 31, 2022, 2021 and 2020 is as follows (shares in thousands):

Years Ended December 31,	2022					2021					2020
	RSUs			Weighted-Average Grant-Date Fair Value per RSU		RSUs			Weighted-Average Grant-Date Fair Value per RSU		RSUs			Weighted-Average Grant-Date Fair Value per RSU
Outstanding, beginning balance		553		$	30.09		601		$	24.96		387		$	43.99
Granted		311			31.70		254			40.34		462			12.89
Vested		(263	)		28.98		(235	)		28.77		(190	)		34.36
Forfeited		(33	)		28.21		(67	)		22.50		(58	)		24.76
Outstanding, ending balance		568		$	31.64		553		$	30.09		601		$	24.96

Compensation cost related to RSUs was $7.5 million ($5.6 million net of statutory tax rate), $6.6 million ($4.9 million net of statutory tax rate), and $6.4 million ($4.7 million net of statutory tax rate) for the years ended  December 31, 2022, 2021 and 2020, respectively. The grant date fair value of RSUs vested during the years ended  December 31, 2022, 2021 and 2020 was $7.6 million, $6.8 million and $6.5 million, respectively. As of December 31, 2022, there was $8.2 million of unrecognized compensation cost related to RSUs which will be recognized over a remaining weighted-average period of 1.4 years.

401(k) Plan: As of December 31, 2022, the 401(k) Plan owned 1,021,194 shares of our common stock. Dividends on shares held by the 401(k) Plan are charged to retained earnings and all shares held by the 401(k) Plan are treated as outstanding in computing our earnings per share.

Share Purchase Program: As announced on February 3, 2022, on February 1, 2022, the Board of Directors authorized us to purchase up to $300.0 million of our common stock at management’s discretion (the “2022 authorization”). The specific timing and amount of any future repurchases will vary based on market conditions, securities law limitations and other factors. As of December 31, 2022, $231.5 million of the 2022 authorization remained available with purchases of 611,000 shares for $18.5 million in March 2022, 1,320,568 shares for $40 million in May 2022 and 366,785 shares for $10 million in September 2022.